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Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in
natriuretic, vasodilatatory, and anti-proliferative effects. In concert, these effects are prone to produce a powerful ventricular unloading and anti-
hypertensive response. LCZ696 (Valsartan/sacubitril) is afirst-in-class angiotensin II-receptorneprilysin inhibitor. LCZ696 is anoveldrugnotonly
for the treatment of heart failure but it is also likely to be a useful antihypertensive drug and may have a preferential effect on systolic pressure. This
review discusses (i) the mechanism of action, pharmacokinetics, and pharmacodynamics of this novel drug, (ii) the efficacy, safety, and tolerability
of LCZ696 in treatment of hypertension from the available trials, (iii) evidence from other contemporary trials on combined Neprilysin inhibitors,
(iv) future trials and areas of research to identify hypertensive patient populations that would most benefit from LCZ696.
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Introduction
In recent years, cell-signalling pathways and pathophysiological
mechanisms have provided pharmacological targets for the develop-
ment of novel antihypertensive drugs. Neprilysin is a neutral endo-
peptidase and its inhibition increases bioavailability of natriuretic
peptides (NPs), bradykinin, and substance P, resulting in natriuretic,
vasodilatatory, and anti-proliferative effects. In concert, these effects
are prone to produce a powerful ventricular unloading and antihy-
pertensive response. Isolated neprilysin inhibitors showed only a
modest effect and hence went out of favour as stand-alone blood-
pressure (BP) lowering agents.1,2 Subsequently, drugs involving com-
bined inhibition of neprilysin with renin–angiotensin–aldosterone
system (RAAS) or endothelin-converting enzyme were developed
and studied. Omapatrilat was the first-in-class representative drug
of dual inhibition of neprilysin and the angiotensin-converting
enzyme (ACE). Omapatrilat showed superior antihypertensive
efficacy compared with other drug classes; however, the increased
frequency and severity of angioedema observed with this drug lead
to its withdrawal.3,4 The increased frequency of angioedema was
attributed to accumulation of bradykinin due to inhibition of ACE,
neprilysin, and aminopeptidase.5 These findings prompted the devel-
opment of agents that combined neprilysin inhibitors with other
molecules such as angiotensin-receptor blockers and endothelin-
converting enzyme inhibitors. Valsartan/sacubitril (LCZ696, Novar-
tis Pharmaceuticals) is a first-in-class angiotensin II-receptor
neprilysin inhibitor (ARNI). Valsartan/sacubitril is a novel drug not
only for the treatment of heart failure but it is also likely to be a
useful antihypertensive drug. The aim of this concise review is to
present the available data of ARNIs and discuss its role in manage-
ment of hypertension.
Mechanism of action
Natriuretic peptides are a group of hormones that have potent
effects on sodium and fluid balance. Additionally, they act to inhibit
RAAS, reduce sympathetic drive, and have both antihypertensive
and anti-proliferative effects.6,7 Three types of NPs have been
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identified: Atrial NP (ANP) and Brain or B-type NP (BNP), released
fromthe atria and left ventricle, respectively, in response to increased
filling pressures and increased cardiac chamber wall stress, act to
promote natriuresis, diuresis, and vasodilation.8 The third, C-type
NP (CNP) is found in the central nervous system, kidneys, and vascu-
lar endothelial cells; however, the significance of this peptide on the
cardiovascular system has not been well established.9,10 Neprilysin
(also known as neutral endopeptidase 24.11) is a zinc-dependent
metallopetidase that catalyses the degradation of various peptides
including ANP, BNP, and bradykinin, as well as contributes to the
breakdown of angiotensin II.11 Thus inhibition of neprilysin in order
to increase circulating levels of NPs has been studied for its thera-
peutic effect on BP. Though neprilysin inhibition alone has little, if
any, antihypertensiveeffect, concomitant inhibitionof bothneprilysin
and RAAS has demonstrated to synergistically lower BP.
Omapatrilat, an inhibitor of neprilysin and ACE is the most studied
vasopeptidase inhibitor. In monotherapy, it has shown greater effi-
cacy in lowering BP than ACE-inhibitors and calcium-channel block-
ers.12,13 However, it was associated with an unacceptable risk of
angioedema due to excessive inhibition of bradykinin degradation
(presumably via neprilysin, ACE, and aminopeptidase P).3– 5 In con-
trast to omapatrilat, in LCZ696, the ACE inhibition has been replaced
with an angiotensin II-receptor blocker (ARB) which has lesser effect
on bradykinin14 and thus a lower risk of angioedema.15,16 Conceptu-
ally, this drug provides the vasodilatory and natriuretic properties of
NPs concomitant with inhibitory effects on endothelin, vasopressin,
sympathetic activity, and RAAS, but with an improved adverse effect
profile17 (Figure 1).
Pharmacokinetics and
pharmacodynamics
LCZ696 is an oral tablet composed of a prodrug AHU377 (which is
rapidly metabolized in to the active neprilysin inhibitor LBQ657 by
enzymatic cleavage of its ethyl ester) and valsartan, a well-established
ARB. These two molecular components are present in a 1:1 molar
ratio. The maximal concentration of the valsartan component of
LCZ696 is reached in 1.7–2.2 h, and 0.5–1.1 h for AHU377 with
the active metabolite LBQ657 at peak concentration within 1.9–
3.5 h. Mean t1/2 values range from 1.1 to 3.6 h for AHU377, 9.9–
11.1 h for LBQ657, and 8.9–16.6 h for valsartan.18 LBQ657 exerts
its inhibitory effect on neprilysin leading to an observed increase in
both atrial natruretic peptide and guanosine monophosphate
(cGMP).18,19 A dose escalation study in 83 healthy participants
showed a maximal 40% increase mean cGMP levels at 4 h and signifi-
cant increases at 12 h post-dose with return to baseline levels at 24 h
after administration of LCZ696.18 In the same study, significant dose-
dependent effects of the valsartan moiety lead to increases in renin
concentration (93–634%), plasma renin activity (280–1768%), and
angiotensin II (241–1188%) compared with placebo. A significant in-
crease of RAAS biomarkers were still observed 24 h after dosing.
These results demonstrated a potent dual neurohormonal effect
of LCZ696 on neprilysin and the angiotensin receptor. Peak concen-
trations of LBQ657 and valsartan were reached within a similar time
frame demonstrating comparable pharmacokinetic properties. The
pharmacodynamics of these two agents is also similar, exemplified
by the maximal concentrations of cGMP and RAAS biomarkers
Figure 1 Schematic diagram showing mechanism of action of LCZ696.
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being reached in parallel at 4 h. This is in contrast with omapatrilat
which exerted delayed neprilysin inhibition when compared with
ACE inhibition.20,21 Though the clinical significance of this distinction
is not currently known, LCZ696 may have a more balanced participa-
tion of its two mechanisms of action in controlling BP which may
potentiate its overall efficacy. Moreover, the sustained pharmacody-
namic effect of both the valsartan and LBQ657 moieties allows for
once-daily dosing of LCZ696 for treatment of hypertension.
Clinical trials of angiotensin
II-receptor neprilysin inhibitor in
hypertension
Relevant articles were identified by searching MEDLINE using the fol-
lowingkeywords andMedical SubjectHeadings (MeSH) terms: nepri-
lysin inhibitor, LCZ696, angiotensin-receptor neprilysin inhibitor,
hypertension, and/or heart failure. We screened the title and abstract
of possibly relevant citations and retrieved all randomized control
trials published until 2015, that studied or reported the effects of
neprilysin inhibitors on BP.
Ruilope et al.22 reported the first proof-of-concept trial with
LCZ696 that investigated the antihypertensive effects of LCZ696
when compared with the angiotensin-receptor blocker—valsartan.
In the multi-centre, randomized, double-blinded, placebo-controlled,
active-comparator study involving 1328 patients of 18–75 years of
age with mild-to-moderate essential hypertension were randomly
assigned to 8 weeks of double-blind treatment in one of eight groups
of daily dose: 100, 200, and 400 mg LCZ696; 80, 160, and 320 mg val-
sartan; 200 mg AHU377; or placebo. The primary outcome of the trial
was the mean sitting diastolic BP difference between the three single-
dose pairwise comparisons of LCZ696 and valsartan doses (100 mg
LCZ696 vs. 80 mg valsartan, 200 mg LCZ696 vs. 160 mg valsartan,
and 400 mg LCZ696 vs. 320 mg valsartan).
The mean age of the trial population was 53 (+10.2) years, with
57% male and about 86% of patients younger than 65 years. The
average duration of hypertension was 6.8 (+7.2) years. LCZ696
provided significantly superior reductions from baseline in mean
sitting diastolic and systolic BP than valsartan at 8 weeks. When
compared with 160 mg valsartan, 200 mg LCZ696 showed a
higher reduction in mean sitting systolic BP (211 vs. 25.69 mmHg,
P ¼ 0.0006) and mean sitting diastolic BP (26.14 vs. 23.17 mmHg,
P ¼ 0.0023). Similarly, compared with 320 mg valsartan, 400 mg
LCZ696 showed a significantly higher reduction in mean sitting
systolic BP (212.5 vs. 26.44 mmHg, P, 0.0001) and mean sitting
diastolic BP (26.85 vs. 24.15 mmHg, P ¼ 0.0055). The reduction
in mean sitting diastolic and systolic BP for 100 mg LCZ696 vs.
80 mg valsartan did not reach statistical significance. In a subgroup
of 427 patients who underwent ambulatory BP monitoring, signifi-
cant differences in 24-h mean ambulatory systolic BP were recorded
for 200 mg LCZ696 vs. 160 mg valsartan (23.23 mmHg) and 400 mg
LCZ696 vs. 320 mg valsartan (25.14 mmHg) for the 8-week treat-
ment period (P, 0.05). However, differences in 24-h mean ambula-
tory diastolic BP between LCZ696 and corresponding valsartan
doses were small and not significant.
Recently, Kario et al.23 published results of second hypertension
trial of LCZ696 which was a multi-centre, randomized, double-
blinded, placebo-controlled of 389 Asian patients aged ≥18 years
with mild-to-moderate essential hypertension. After a 4-week
run-in period, patients were randomized to 100, 200, or 400 mg
LCZ696 or placebo for an 8-week double-blind period. The
primary endpoint was mean difference across the three single-dose
pairwise comparisons of LCZ696 vs. placebo (100, 200, and
400 mg LCZ696 vs. placebo) in clinic diastolic BP after the 8-week
treatment period. When compared with placebo, the mean differ-
ences in change from baseline in clinic diastolic BP was 27.84,
27.29, and28.76 mmHg forLCZ696 100, 200, and 400 mg, respect-
ively. Likewise, compared with placebo, the mean differences in
change from baseline in clinic systolic BP were 211.86, 212.57,
and 215.38 mmHg for LCZ696 100, 200, and 400 mg, respectively.
All doses of LCZ696 were associated with significant reductions in
24-h, daytime, and nighttime ambulatory systolic, diastolic, and
pulse pressures (P, 0.0001).
Compared with Caucasian patients, BP reduction by LCZ696
tended to be greater in Asian patients with hypertension indicating
that this drug may be particularly suitable in this population.23 Asian
hypertensive patients are characterized by higher salt sensitivity and
higher salt intake, resulting in suppression of renin–angiotensin
system.24,25 These characteristics may result in higher prevalence of
stroke, which is more directly associated with systolic BP. Thus,
the increase in NPs by neprilysin inhibition in combination with ARB
exerts an incremental effect on BP compared with ARB-monotherapy
in Asian hypertensive patients (e.g. salt sensitive orelderly). In addition,
LCZ696 may also be an effective drug in resistant hypertensive
patients.26 Of note, compared with the same dose of valsartan,
LCZ696 decreased systolic BP more than diastolic BP, resulting in a re-
ductionofpulsepressure22 (Figure2).Although theprecisemechanism
remains to be elucidated, the direct effect of NPs and ARB on the vas-
cular properties and/or reduced circulating volume may play a part in
the preferential effect of LCZ696 on systolic BP.
Effects of angiotensin II-receptor
and neprilysin inhibitor on blood
pressure in patients with heart
failure
The effect of LCZ696 on BP was evaluated in patients with HF with
preserved ejection fraction (HFpEF) in the Prospective comparison of
ARNI with ARB on Management Of heart failUre with preserved ejectioN
fracTion (PARAMOUNT) trial.27 This was a Phase II, randomized,
parallel-group, double-blind, multicentre trial in patients with
HFpEF. Participants were randomly assigned to LCZ696 titrated to
200 mg twice daily or valsartan titrated to 160 mg twice daily. The
trial reported BP changes in both arms at 12 and 36 weeks as one
of the secondary outcomes. The trial involved 301 patients with
HFpEF of which about 93% had hypertension. After 12 weeks of
treatment, BP was reduced by 29.3 mmHg systolic and 24.9
mmHg diastolic in the LCZ696 group. In the valsartan group, the sys-
tolic BP was reduced by 22.9 mmHg while the diastolic BP was
reduced by22.1 mmHg (P ¼ 0.001 for systolic and P ¼ 0.09 for dia-
stolic BP differences). The significant higher reduction in BP by
LCZ696 when compared with valsartan persisted at 36 weeks.
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While all the previous trials provided insights into the short term
antihypertensive efficacy of LCZ696, the recently published Prospect-
ive comparison of ARNIwith ACEI toDetermine Impact onGlobalMortality
and morbidity in Heart Failure trial (PARADIGM-HF)28 provided some
data on the long-term effects of LCZ696 in patients with chronic
heart failure and a reduced ejection fraction (HFrEF). The trial
involved 8442 HFrEF patients with 71% patients having history of
hypertension. LCZ696 (200 mg twice daily) was superior to Enalapril
(10 mg twice daily) in reducing the risksof deathand heart failurehos-
pitalization. In the Supplementary material published with the study
results, LCZ696 showed a significant reduction in systolic BP when
compared with Enalapril [mean difference 22.7 (23.07 to 22.34
mmHg, P, 0.001)] over a period of 3 years. It is unclear whether
the favourable effects of LCZ696 on death and heart failure hospital-
ization is mediated primarily by reduction in BP or is independent
of changes in BP.
Safety and tolerability of
angiotensin II-receptor and
neprilysin inhibitor in
hypertension trials
LCZ696 showedrelatively goodsafety profile. In the studyby Ruilope
et al.22 during the 8-week treatment period, the most common
adverse event was pruritus (2%) for LCZ696 200 mg and diarrhoea
(3%) for LCZ696 400 mg. The rates were non-significant when com-
pared with Valsartan. No cases of angioedema or deaths were
reported. Discontinuation due to adverse events was 2% for
LCZ696 200 mg, 1% each for LCZ696 400 mg, Valsartan 80 and
160 mg while 0 for Valsartan 400 mg. In the trial by Kario et al.,23
the most common adverse event was nasopharyngitis and upper re-
spiratory tract information. Incidence of dizziness was low (2.8%) and
was not dose related. These side-effects was numerically higher in
placebo groups when compared with LCZ696 100, 200, or
400 mg. Discontinuation due to adverse side-effects was 2% for
LCZ696 200 mg, 1% for LCZ696 400, and 4.3% for placebo.
Overall, all doses of LCZ696 were well tolerated, and no cases of
angioedema or death were reported in either of these trials. Of
note, patients with a history of angioedema were excluded in both
the trials.
LCZ696 showed no significant change in heart rate from baseline
in any of the trials.22,23,27,28 Ruilope et al.22 assessed orthostatic BP
changes with LCZ696 and reported an incidence of 4–7%, with
the lowest value in the 400 mg LCZ696 group. Future trials should
study the occurrence of orthostatic hypotension at various
dosages of LCZ696, since it is an important consideration in elderly
patients. In addition, the effect of dietary salt intake on the response
to this drug has not been previously studied and warrants future
investigation.
Angiotensin II-receptor and
neprilysin inhibitor in hypertension
and specific comorbidities
Both diabetes and chronic kidney disease are associated with high
prevalence of hypertension. The efficacy of ARNI in this important
patient groups remains to be evaluated since in both the hypertension
trials, patients with Type 1 and 2 diabetes and renal disease were
excluded.22,23 Kario et al.23 found a negligible change in serum creatin-
ine in placebo and LCZ696 groups. The mean change in serum creatin-
ine from baseline was 0.02 mg/dL in the placebo group and 0.01 and
0.03 mg/dL in LCZ696 200 and 400 mg, respectively. In the PARA-
MOUNT trial involving patients with HFpEF, treatment with
LCZ696 for 36 weeks resulted in lower serum creatinine and higher
estimated glomerular filtration rate (eGFR) compared with valsar-
tan.29 The mean serum creatinine increase was 0.03 mg/dL in
LCZ696 group and 0.09 mg/dL in the valsartan group (P ¼ 0.007).
Accordingly, the decline in eGFR was lower in the LCZ696 group
than in the valsartan group (21.5 vs. 25.2 mL/min per 1.73 m2; P ¼
0.002). Moreover, in a recent meta-analysis, both omapatrilat and
LCZ696demonstrateda favourableeffect onrenal functioncompared
with ACE-inhibitors or ARB monotherapy in patients with heart
failure.30 It remains to be seen whether similar nephro-protective
effect of LCZ696 can be found in patients with hypertension.
Figure 2 Change in mean (A) systolic and (B) diastolic blood pressure from baseline in three randomized controlled trials. Ruilope et al.22 com-
pared LCZ696 400 mg vs. valsartan 320 mg over 8 weeks. The PARAMOUNT trial compared LCZ696 200 mg twice daily vs. valsartan 160 mg twice
daily over 12 weeks. Kario et al.23 compared LCZ696 400 mg vs. placebo over 8 weeks.
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Neprilysin inhibition and
Alzheimer’s disease
Vodovar et al.31 recently warned that the chronic use of neprilysin inhi-
bitors may compromise b-amyloid peptide degradation in the brain,
thereby possibly accelerate progression of Alzheimer’s disease and
cerebral amyloid angiopathy in patients at risk. In pre-clinical studies,
mostly involving animal models, neprilysin inhibition has been asso-
ciated with development of Alzheimer’s dementia-like disease.32,33
Theseobservations need tobe thoroughly tested in clinical trials. If con-
firmed in human subjects, this would be of much greater concern in
hypertensive patients who are treated for years and even decades
than in heart failure where survival is curtailed. Conceivably, the poten-
tial adverse effects of sacubitril onb-amyloidpeptidedegradationmight
be counterbalanced by ARB’s beneficial vascular effects.34 Regardless,
this clearly indicates that the safety associated with the chronic use of
neprilysin inhibitors, including LCZ696, needs to be scrutinized espe-
cially in patients at-risk such as those with mild cognitive impairment.
Other combined neprilysin
inhibitor
Daglutril (Solvay Pharmaceuticals) is the first-in-class dual neprilysin–
endothelin-converting enzyme inhibitor.35 Endothelin-converting
enzyme is implicated in conversion of Big-Endothelin1 into active
endothelin-1 which binds to endothelin type-A receptors and causes
vasoconstricton and increased anti-NPs.36 Hence neprilysin and
endothelin converting enzyme inhibition are likely to exert antihyper-
tensive efficacy. However, till date, only one randomized control trial
have been published evaluating the antihypertensive efficacy of
daglutril involving patients with type 2 diabetes and nephropathy.35
In a small randomized cross-over, double-blind placebo-controlled
trial of 42 patients, when compared with placebo, 8 weeks of daglutril
(300 mg/day)wasassociatedwith significant reductionofofficesystolic
BP (25.4 mmHg, P ¼ 0.028) but not diastolic BP (21.8 mmHg,
P ¼ 0.245). The drug was well tolerated and no serious treatment-
related adverse events were reported in the trial.
Ongoing trials of angiotensin
II-receptor and neprilysin
inhibitor in hypertension
Currently, several trials are investigating the efficacy and safety of
LCZ696 in treatment of hypertension. The Prospective Comparison
of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin Receptor
Blocker Measuring Arterial Stiffness in the Elderly (PARAMETER) trial
aims to compare the effect of LCZ696 vs. olmesartan on aortic
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Table 1 On-going clinical trials of LCZ696 in hypertensiona
Trial number Patient population Brief title Comparator
NCT01785472 Essential hypertension Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian
Patients With Essential Hypertension
Olmesartan
NCT01599104 Essential hypertension Efficacy and Safety of LCZ696 in Comparison to Olmesartan in
Japanese Patients With Essential Hypertension
Olmesartan
NCT01870739 Essential hypertension A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in
Subjects With Hypertension
Olmesartan
NCT01615198 Essential hypertension Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly
Patients With Essential Hypertension
Olmesartan
NCT01681576 Salt-sensitive hypertension Assessment of LCZ696 and Valsartan in Asian Patients With
Salt-sensitive Hypertension
Valsartan
NCT01256411 Essential hypertension A Long-term (12 Months) Safety, Tolerability and Efficacy Study of
LCZ696 in Patients With Essential Hypertension
NA
NCT01601470 Mild-to-moderate
hypertension
Evaluation of Drug-drug Interaction Between LCZ696 and Sildenafil in
Subjects With Mild to Moderate Hypertension
Sildenafil
NCT01353508 Hypertension; heart failure
and healthy volunteers
Sodium Excretion of LCZ696 in Patients With Hypertension; Heart
Failure and Healthy Volunteers
Valsartan
NCT01692301 Hypertension Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in
Elderly Patients With Hypertension
Olmesartan, Amlodipine,
Hydrochlorthiazide
NCT01663233 Essential hypertension Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in
Comparison With Amlodipine 5 mg in Hypertensive Patients Not
Responding to Amlodipine
Amlodipine
NCT01646671 Severe hypertension Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe
Hypertensive Patients
NA
NCT01631864 Hypertension, concurrent
obesity
Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in
Obese Hypertensive Subjects
Amlodipine
ISRCTN11958993 Chronic kidney disease Randomized multicentre pilot study of LCZ696 vs. Irbesartan in
patients with chronic kidney disease: UK Heart And Renal
Protection (HARP)-III
Irbesartan
aFrom ClinicalTrials.gov and International Standard Randomized Controlled Trials Number (ISRCTN) Register, NA, not applicable.
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hemodynamics and ambulatory BP.37 PARAMETER will include an
estimated 432 patients with essential hypertension ≥60 years
(mean sitting systolic BP 150–180 mmHg and pulse pressure .60
mmHg) who will be randomized either to once daily LCZ696
200 mg or olmesartan 40 mg. The primary endpoint is change in
central aortic systolic pressure at 12 weeks measured non-invasively
by waveform analysis using a brachial BP cuff linked to computer soft-
ware. Other on-ongoing clinical trials, retrieved by searching Clinical-
Trials.gov and International Standard Randomized Controlled Trials
Number (ISRCTN) Registry, are listed in Table 1.
Perspective
Antihypertensive therapy with modern drugs, given as monotherapy
or in combination, allows lowering of BP with comfort and conveni-
ence. Many drugs have an adverse effect profile close to or even
better than placebo, are inexpensive, and allow once-daily dosing.
Even resistant hypertension can most often be managed with com-
bination therapy without causing inconvenient adverse effects.
However, the antihypertensive efficacy of most commonly used
drugs is remarkably similar; BP decreases to about the same extent
whether therapy is initiated with a diuretic, a calcium-channel
blocker, a beta-blocker, or an RAAS blocker. This would indicate
that the risk/benefit ratio of many antihypertensive drugs is exceed-
ingly low and some agents such as amlodipine have outstanding
outcome data. Clearly, this represents a challenging milieu for intro-
ducing a new drug class. However, since safety is unlikely to be sur-
passed, a new arrival will have to document greater efficacy than
other antihypertensive agents either in lowering the surrogate, i.e.
BP, preferentially systolic and/or visit-to-visit BP variability and,
even more importantly, in improving end-organ damage (vasculopa-
thy, retinopathy, left-ventricular hypertrophy, and nephropathy) and
outcomes (stroke, coronary artery disease, heart failure, and death).
The outcomes data so far accumulated in heart failure seem to indi-
cate that this may be indeed the case with Valsartan/sacubitril
(LCZ696).
Conclusions
From the available evidence, LCZ696 have shown impressive reduc-
tion in systolic anddiastolic BP; however, the long-term antihyperten-
sive efficacyof LCZ696 has not been fully evaluated. Also the effect of
LCZ696 on cardiovascular outcomes in patients with hypertension is
unknown. In the PARADIGM trial, LCZ696 showed a striking reduc-
tion in cardiovascular mortality and morbidity in patients with HFrEF.
However, it is to be seen whether LCZ696 confers similar long-term
prognostic benefits in patients with hypertension. Further studies
need to be conducted to elucidate the role of LCZ696 in patients
with (i) diabetes, (ii) chronic kidney disease, (iii) elderly, (iv) resistant
hypertension. Since blacks were underrepresented in the two pub-
lished hypertension trials, future trials should include adequate
black population. Most importantly, studies needs to be conducted
comparing antihypertensive efficacy and outcome of LCZ696 with
other drug classes such as calcium-channel blockers and diuretics.
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